Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AAR

- PMLiVE

Amgen hit as Kyprolis fails myeloma study

Inability to improve overall survival could dent expanded use prospects

- PMLiVE

Amgen closes on second-line use for Kyprolis

Multiple myeloma therapy posts positive interim phase III results

- PMLiVE

Amgen cuts workforce and facilities despite profit leap

US biopharma plans 12-15 per cent workforce reduction

- PMLiVE

Amgen launches bowel cancer web portal in Spain

Aims to help healthcare professionals understand about personalised medicine

- PMLiVE

Two blood cancer drugs among CHMP recommendations

Five new drugs, including Janssen’s Imbruvica and Gilead’s Zydelig, backed for use in Europe

- PMLiVE

Amgen’s Sensipar follow-up clears phase III trial

AMG 416 meets objectives in hyperparathyroidism

EU flag

EMA transparency policy delayed over ‘wording’

Regulation on access to trial data postponed until October

- PMLiVE

GSK wins approval for skin cancer drug Mekinist in EU

Will compete with Roche’s Zelboraf and BMS’ Yervoy in melanoma

- PMLiVE

Amgen and Boehringer drugs win FDA breakthrough status

Leukaemia drug and Pradaxa antidote will benefit from accelerated regulatory processes

- PMLiVE

Merck could win anti-PD1 therapy race in Europe

EMA accepts filing for promising pembrolizumab in melanoma

Novartis building

Novartis pulls EMA application for expanded Tasigna use

And Boehringer confirms it won't seek approval for faldaprevir as it exits hepatitis C

- PMLiVE

Biosimilar Lantus leads CHMP opinions

Boehringer and Lilly’s insulin one of six new medicines recommended for EU approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links